Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) Enterprise Value (2021 - 2025)

Kezar Life Sciences' Enterprise Value history spans 5 years, with the latest figure at -$90.2 million for Q3 2025.

  • For Q3 2025, Enterprise Value rose 39.2% year-over-year to -$90.2 million; the TTM value through Sep 2025 reached -$90.2 million, up 39.2%, while the annual FY2024 figure was -$132.2 million, 34.33% up from the prior year.
  • Enterprise Value for Q3 2025 was -$90.2 million at Kezar Life Sciences, up from -$100.8 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$90.2 million in Q3 2025 and bottomed at -$306.8 million in Q2 2022.
  • The 5-year median for Enterprise Value is -$179.8 million (2024), against an average of -$187.4 million.
  • The largest annual shift saw Enterprise Value tumbled 140.46% in 2022 before it soared 39.2% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$208.4 million in 2021, then crashed by 32.74% to -$276.6 million in 2022, then grew by 27.19% to -$201.4 million in 2023, then surged by 34.33% to -$132.2 million in 2024, then surged by 31.78% to -$90.2 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Enterprise Value are -$90.2 million (Q3 2025), -$100.8 million (Q2 2025), and -$114.4 million (Q1 2025).